Protein a sepharose 4b conjugate

The Epstein-Barr Virus-transformed B-Lymphocytes (GM02675, GM02676, GM02678, GM02679, GM02812, GM02765, GM02741 and GM03027) were purchased from Coriell Institute for Medical Research (CIMR, Camden, New Jersey). The clinical data such as age, gender, and race were included in supplemental Table 1. Cells were maintained in RPMI-1640 Medium (ATCC® 30–2001™) supplemented with fetal bovine serum (FBS) (Thermo Scientific, 16000044) as suggested by CIMR. When cells were grown to the required amount, we collected them by centrifugation at 200 g for 10 min, washed twice with ice cold PBS (Gibco, 10010023), and stored as dry cell pellets at −20 °C until use. The W6/32 (HLA-I) and IVA12 (HLA-II) monoclonal antibodies were produced from HB95 (ATCC® HB-95™) and HB145 (ATCC® HB-145™) cells that were purchased from American Type Culture Collection (ATCC) and grown in DMEM (ATCC® 30–2002™) medium supplemented with FBS to a final concentration of 10%. The W6/32 and IVA12 monoclonal antibodies were purified from the growth medium using protein A-Sepharose 4B conjugate (Invitrogen, 101042). The purified antibodies were stored at −20 °C for future use.